Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

NASDAQ:SNSE - US81728A2078 - Common Stock

7.8323 USD
-0.28 (-3.42%)
Last: 8/26/2025, 4:30:02 PM
Fundamental Rating

1

Taking everything into account, SNSE scores 1 out of 10 in our fundamental rating. SNSE was compared to 547 industry peers in the Biotechnology industry. While SNSE seems to be doing ok healthwise, there are quite some concerns on its profitability. SNSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNSE had negative earnings in the past year.
In the past year SNSE has reported a negative cash flow from operations.
SNSE had negative earnings in each of the past 5 years.
In the past 5 years SNSE always reported negative operating cash flow.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SNSE has a worse Return On Assets (-84.39%) than 70.02% of its industry peers.
SNSE has a Return On Equity of -98.20%. This is comparable to the rest of the industry: SNSE outperforms 45.70% of its industry peers.
Industry RankSector Rank
ROA -84.39%
ROE -98.2%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

SNSE has more shares outstanding than it did 1 year ago.
SNSE has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SNSE has been reduced compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -12.59, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
SNSE has a worse Altman-Z score (-12.59) than 76.60% of its industry peers.
SNSE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SNSE has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: SNSE outperforms 50.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.59
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 7.64 indicates that SNSE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.64, SNSE is in the better half of the industry, outperforming 71.30% of the companies in the same industry.
SNSE has a Quick Ratio of 7.64. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
SNSE's Quick ratio of 7.64 is fine compared to the rest of the industry. SNSE outperforms 71.66% of its industry peers.
Industry RankSector Rank
Current Ratio 7.64
Quick Ratio 7.64
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

SNSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.70%, which is quite good.
EPS 1Y (TTM)9.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNSE will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.79%
EPS Next 2Y24.29%
EPS Next 3Y5.32%
EPS Next 5Y8.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.29%
EPS Next 3Y5.32%

More info and screens

0

5. Dividend

5.1 Amount

SNSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (8/26/2025, 4:30:02 PM)

7.8323

-0.28 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners7.69%
Inst Owner Change-94.54%
Ins Owners2.11%
Ins Owner Change0%
Market Cap9.87M
Analysts86.67
Price Target68.85 (779.05%)
Short Float %0.96%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.51%
Min EPS beat(2)-18.53%
Max EPS beat(2)31.55%
EPS beat(4)2
Avg EPS beat(4)3.05%
Min EPS beat(4)-18.53%
Max EPS beat(4)31.55%
EPS beat(8)5
Avg EPS beat(8)3.3%
EPS beat(12)8
Avg EPS beat(12)2.41%
EPS beat(16)10
Avg EPS beat(16)1.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1587.5%
EPS NQ rev (1m)11.88%
EPS NQ rev (3m)-3876%
EPS NY rev (1m)5.75%
EPS NY rev (3m)-1986.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-21.31
EYN/A
EPS(NY)-10.92
Fwd EYN/A
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.26
OCFYN/A
SpS0
BVpS21.68
TBVpS21.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.39%
ROE -98.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.64
Quick Ratio 7.64
Altman-Z -12.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.18%
EPS Next Y14.79%
EPS Next 2Y24.29%
EPS Next 3Y5.32%
EPS Next 5Y8.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.91%
EBIT Next 3Y-12.07%
EBIT Next 5YN/A
FCF growth 1Y36.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.43%
OCF growth 3YN/A
OCF growth 5YN/A